Review



agonism cd137l  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems agonism cd137l
    Agonism Cd137l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/agonism cd137l/product/R&D Systems
    Average 93 stars, based on 10 article reviews
    agonism cd137l - by Bioz Stars, 2026-03
    93/100 stars

    Images



    Similar Products

    agonism cd137l  (R&D Systems)
    93
    R&D Systems agonism cd137l
    Agonism Cd137l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/agonism cd137l/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    agonism cd137l - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    human cd137l  (R&D Systems)
    92
    R&D Systems human cd137l
    Nectin-4/CD137 Bicycle TICA cause tumor regression in vivo. (A) Jurkat-CD137 reporter cells were cocultured with CT26 clone overexpressing Nectin-4 (CT26-Nectin-4) and treated with BCY10572 (1:1 Bicycle TICA), BCY11863 (1:2 Bicycle TICA), or <t>CD137L.</t> Data are mean ± s.d. ( n ≥ 3 replicates). (B) Plasma concentration of BCY10572 and BCY11864 when dosed at 15 mg/kg by intraperitoneal injection to CD-1 mouse. (C, D) CT26-Nectin-4 tumor-bearing huCD137-Balb/c (C) or wild type Balb/c (D) mice were treated with daily doses of vehicle or BCY10572 (1 or 5 mg/kg) and tumor growth was monitored. Data are mean ± standard error of the mean (SEM) ( n = 5 mice/treatment cohort). TV: tumor volume.
    Human Cd137l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cd137l/product/R&D Systems
    Average 92 stars, based on 1 article reviews
    human cd137l - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier
    cd137l  (R&D Systems)
    91
    R&D Systems cd137l
    Nectin-4/CD137 Bicycle TICA cause tumor regression in vivo. (A) Jurkat-CD137 reporter cells were cocultured with CT26 clone overexpressing Nectin-4 (CT26-Nectin-4) and treated with BCY10572 (1:1 Bicycle TICA), BCY11863 (1:2 Bicycle TICA), or <t>CD137L.</t> Data are mean ± s.d. ( n ≥ 3 replicates). (B) Plasma concentration of BCY10572 and BCY11864 when dosed at 15 mg/kg by intraperitoneal injection to CD-1 mouse. (C, D) CT26-Nectin-4 tumor-bearing huCD137-Balb/c (C) or wild type Balb/c (D) mice were treated with daily doses of vehicle or BCY10572 (1 or 5 mg/kg) and tumor growth was monitored. Data are mean ± standard error of the mean (SEM) ( n = 5 mice/treatment cohort). TV: tumor volume.
    Cd137l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd137l/product/R&D Systems
    Average 91 stars, based on 1 article reviews
    cd137l - by Bioz Stars, 2026-03
    91/100 stars
    		  Buy from Supplier
    recombinant human cd137l  (R&D Systems)
    90
    R&D Systems recombinant human cd137l
    Nectin-4/CD137 Bicycle TICA cause tumor regression in vivo. (A) Jurkat-CD137 reporter cells were cocultured with CT26 clone overexpressing Nectin-4 (CT26-Nectin-4) and treated with BCY10572 (1:1 Bicycle TICA), BCY11863 (1:2 Bicycle TICA), or <t>CD137L.</t> Data are mean ± s.d. ( n ≥ 3 replicates). (B) Plasma concentration of BCY10572 and BCY11864 when dosed at 15 mg/kg by intraperitoneal injection to CD-1 mouse. (C, D) CT26-Nectin-4 tumor-bearing huCD137-Balb/c (C) or wild type Balb/c (D) mice were treated with daily doses of vehicle or BCY10572 (1 or 5 mg/kg) and tumor growth was monitored. Data are mean ± standard error of the mean (SEM) ( n = 5 mice/treatment cohort). TV: tumor volume.
    Recombinant Human Cd137l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human cd137l/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    recombinant human cd137l - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Nectin-4/CD137 Bicycle TICA cause tumor regression in vivo. (A) Jurkat-CD137 reporter cells were cocultured with CT26 clone overexpressing Nectin-4 (CT26-Nectin-4) and treated with BCY10572 (1:1 Bicycle TICA), BCY11863 (1:2 Bicycle TICA), or CD137L. Data are mean ± s.d. ( n ≥ 3 replicates). (B) Plasma concentration of BCY10572 and BCY11864 when dosed at 15 mg/kg by intraperitoneal injection to CD-1 mouse. (C, D) CT26-Nectin-4 tumor-bearing huCD137-Balb/c (C) or wild type Balb/c (D) mice were treated with daily doses of vehicle or BCY10572 (1 or 5 mg/kg) and tumor growth was monitored. Data are mean ± standard error of the mean (SEM) ( n = 5 mice/treatment cohort). TV: tumor volume.

    Journal: Journal of Medicinal Chemistry

    Article Title: Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology

    doi: 10.1021/acs.jmedchem.2c00505

    Figure Lengend Snippet: Nectin-4/CD137 Bicycle TICA cause tumor regression in vivo. (A) Jurkat-CD137 reporter cells were cocultured with CT26 clone overexpressing Nectin-4 (CT26-Nectin-4) and treated with BCY10572 (1:1 Bicycle TICA), BCY11863 (1:2 Bicycle TICA), or CD137L. Data are mean ± s.d. ( n ≥ 3 replicates). (B) Plasma concentration of BCY10572 and BCY11864 when dosed at 15 mg/kg by intraperitoneal injection to CD-1 mouse. (C, D) CT26-Nectin-4 tumor-bearing huCD137-Balb/c (C) or wild type Balb/c (D) mice were treated with daily doses of vehicle or BCY10572 (1 or 5 mg/kg) and tumor growth was monitored. Data are mean ± standard error of the mean (SEM) ( n = 5 mice/treatment cohort). TV: tumor volume.

    Article Snippet: Recombinant proteins: human CD137 (92 204B, R&D Systems) and human CD137L (2295-4L-025, R&D Systems) were purchased.

    Techniques: In Vivo, Clinical Proteomics, Concentration Assay, Injection